DAX23.933 -0,4%ESt505.371 -0,1%Top 10 Crypto14,42 +1,2%Dow42.216 +0,3%Nas19.176 +0,4%Bitcoin93.607 +0,9%Euro1,1342 -0,3%Öl63,89 -0,4%Gold3.294 -0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 RENK RENK73 Tesla A1CX3T HENSOLDT HAG000 Lufthansa 823212 BYD A0M4W9 Siemens Energy ENER6Y Infineon 623100 Apple 865985 Mercedes-Benz Group (ex Daimler) 710000 Deutsche Telekom 555750 thyssenkrupp 750000 D-Wave Quantum A3DSV9 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach Trump-Berufungserfolg: DAX vor verhalten freundlicher Eröffnung -- Börsen in Fernost geben klar nach -- MDAX-Wechsel im Juni: JPMorgan sieht IONOS als Ersatz für JENOPTIK -- Bitcoin im Fokus
Top News
Sanofi-Aktie: Arznei Itepekimab zeigt in Studien gemischte Ergebnisse Sanofi-Aktie: Arznei Itepekimab zeigt in Studien gemischte Ergebnisse
Bitcoin fängt sich nach Verlusten der Vortage bei 106.000 US-Dollar Bitcoin fängt sich nach Verlusten der Vortage bei 106.000 US-Dollar
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
"600% Momentum-Strategie": Aktien hebeln und Gewinne maximieren - sichern Sie sich jetzt das Kennenlernangebot für nur 39 Euro (statt 69 Euro) im Monat!

Apricus Biosciences Aktie

Handeln
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Bei einem anderen Broker handelnSmartphone
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PDK8

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS81577F1093

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSEEL

Apricus Biosciences Aktien News

DatumMeistgelesen
PR NewswireSeelos Announces Second Postponement of its Annual Meeting of Stockholders
PR NewswireSeelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market
PR NewswireSeelos Announces Postponement of its Annual Meeting of Stockholders
PR NewswireSeelos Therapeutics Announces 1-for-16 Reverse Stock Split
PR NewswireSeelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD
PR NewswireSeelos Therapeutics Announces 1-for-8 Reverse Stock Split
PR NewswireSeelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations
PR NewswireSeelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
PR NewswireSeelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary ...
PR NewswireLeading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
PR NewswireSeelos Therapeutics, Inc. Releases Letter to its Stockholders
PR NewswireSeelos Therapeutics Announces 1-for-30 Reverse Stock Split
PR NewswireSeelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
PR NewswireSeelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
PR NewswireSeelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease
PR NewswireSeelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
PR NewswireSeelos Therapeutics Provides Second Quarter 2023 Clinical Update
PR NewswireSeelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Maj...
PR NewswireSeelos Therapeutics to Participate in Two Upcoming Healthcare Conferences
PR NewswireSeelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results
PR NewswireSeelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
PR NewswireSeelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program
PR NewswireSeelos Therapeutics Announces Business Update on its Key Programs
PR NewswireSeelos Therapeutics to Participate in 43rd Annual Cowen Health Care Conference
PR NewswireSeelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
PR NewswireSeelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit
PR NewswireSeelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)
PR NewswireSeelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event
PR NewswireSeelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease
PR NewswireSeelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022
PR NewswireSeelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022
PR NewswireSeelos Therapeutics to Participate in the Guggenheim 4th Annual Immunology and Neurology Day
PR NewswireSeelos Therapeutics to Sponsor and Participate in Wonderland, the World's Leading Psychedelic Event
PR NewswireSeelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar Ataxia
PR NewswireSeelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the A...
PR NewswireSeelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patient...
PR NewswireSeelos Therapeutics to Participate in the Guggenheim Nantucket Therapeutics Conference
PR NewswireSeelos Therapeutics to Participate in Two Upcoming Psychedelic Conferences
PR NewswireSeelos Therapeutics Receives a Research and Development Grant from The Michael J. Fox Foundation for Parkinson's Research for SLS-004
PR NewswireSeelos Therapeutics Doses First Patient in an Open Label Basket Study of SLS-005 in Amyotrophic Lateral Sclerosis in Australia and Provides an Enrollment Update of its Study on the HEALEY ALS Platform
Wer­bung

Apricus Biosciences News

Apricus Biosciences News: auf dieser Seite finden Sie alle Apricus Biosciences News und Nachrichten zur Apricus Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Apricus Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Apricus Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.